Proportion of countries in which a given testing option is the most cost-effective (with 10% influenza prevalence among COVID-like, non-COVID patients).

<p>The “most cost-effective option” is the option most likely to be cost-effective based on simulation of 1,000 parameter sets. PCR, polymerase chain reaction; RDT, rapid diagnostic tests; TCZ, tocilizumab; LICs, low-income countries (27 countries); LMICs, lower-middle-income countries (54 cou...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Gabrielle Bonnet (11614471) (author)
مؤلفون آخرون:	John Bimba (17445769) (author), Chancy Chavula (17445772) (author), Harunavamwe N. Chifamba (17445775) (author), Titus H. Divala (10147334) (author), Andres G. Lescano (9733735) (author), Mohammed Majam (8299185) (author), Danjuma Mbo (17445778) (author), Auliya A. Suwantika (17445781) (author), Marco A. Tovar (4519339) (author), Pragya Yadav (358042) (author), Obinna Ekwunife (3512240) (author), Collin Mangenah (2282995) (author), Lucky G. Ngwira (10199168) (author), Elizabeth L. Corbett (8150859) (author), Mark Jit (43662) (author), Anna Vassall (144677) (author)
منشور في:	2024
الموضوعات:	Medicine Biotechnology Cancer Science Policy Infectious Diseases Virology substantial uncertainty around healthcare provider perspective 6 receptor blockers patient &# 8217 decision tree model negative test results current covid mortality covid symptom alleviation side effects depend high initial index low initial index treatment side effects inform treatment decisions country income level side effects high index patient may model due positive results differentiating results treatment options inform treatment available treatment xlink "> unintended effects underlying illness primary limitation optimal algorithm narrow set like symptoms like illnesses like illness like disease insufficient evidence influenza outbreaks influenza cases influenza ), existing analyses economic impacts critical illness coronavirus disease combinations ). better characterize almost always
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Proportion of countries in which a given testing option is the most cost-effective (with 10% influenza prevalence among COVID-like, non-COVID patients).

مواد مشابهة